Laura Tadvalkar | Managing Director
RA Capital Management
Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Laura works on new company creation and early-stage investments, and serves as a Board Director for Hemab, Hyku Biosciences, and Typewriter Therapeutics. She previously served as a Board Director for Mariana Oncology prior to its acquisition by Novartis, and as Board Chair for Aliada Therapeutics prior to its acquisition by AbbVie. Prior to RA, Laura was a Principal at MP Healthcare Venture Management and a Consultant at Clarion Healthcare. Laura holds a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University.
Appearances:
Pre-Conference Day - World Orphan Drug Congress USA 2026 @ 14:00
Venture Capital for Rare Disease; How To Secure Investment for Rare Disease Startups
This workshop will:
- Identify the key investment criteria VCs apply to rare-disease startups—including scientific rigor, platform potential, and clarity of clinical path
- Highlight what VCs view as strong commercial viability in rare disease, from market shaping to patient-access strategies.
- Provide insights on how startups can present compelling data, leadership readiness, and long-term value creation that align with investor expectations
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events